Crestor - Astrazeneca
Please complete the eligibility questionnaire below. The questions apply to the study patent and each reference you submit for this study.
The patent in this study is a reissue of US 5,260,444. The reissue application was filed on August 27, 1998, more than 2 years after the â€˜444 Patent issued. A reissue patent application filed more than 2 years after issuance can only seek to narrow the claims of the original patent. The only claims allowed in the reissue application were claims 6, 7 and 8. Therefore Re37,314 only covers the specific compound of claim 6 and the sodium or calcium salts thereof.
During the prosecution of the reissue application, the applicant successfully argued that the chemical composition shown in claim 6 was not anticipated or obvious. A copy of the imaged filewrapper is available on the USPTO website. You can access the filewrapper by using the PAIR function at the USPTO site.
The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt.
Become a Researcher
To date, Article One has paid out $7,190,092 to the Researchers.
Choose your work
Select research projects that suit your personal preferences.
Receive monetary compensation for submitting high-quality research.
Learn while you earn
Explore new tech areas as you develop your research skills.